Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00787969 · ClinicalTrials.gov registry record · Phase 1
Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
A Phase 1 study of Lymphoma, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
- 20
- Study locations
NCT00787969: Completed Phase 1 study of Lymphoma, sponsored by Alliance for Clinical Trials in Oncology.
NCT00787969 is a Phase 1 study of Lymphoma that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 74 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00787969, a Phase 1 study of Lymphoma, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase I/II trial studies the side effects and best dose of temsirolimus when given together with cladribine and rituximab and to see how well it works in treating patients with newly diagnosed mantle cell lymphoma. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as cladribine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Temsirolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving temsirolimus together with cladribine and rituximab may kill more cancer cells.
Conditions Studied
Interventions
- BIOLOGICAL Filgrastim
- BIOLOGICAL Pegfilgrastim
- BIOLOGICAL rituximab
- DRUG temsirolimus
- DRUG cladribine
Study Locations (20)
Illinois
- Illinois CancerCare - Bloomington - Bloomington
- St. Joseph Medical Center - Bloomington
- Graham Hospital - Canton
- Illinois CancerCare - Canton - Canton
- Illinois CancerCare - Carthage - Carthage
- Memorial Hospital - Carthage
- Eureka Community Hospital - Eureka
- Illinois CancerCare - Eureka - Eureka
- Galesburg Clinic, PC - Galesburg
- Illinois CancerCare - Galesburg - Galesburg
- Illinois CancerCare - Havana - Havana
- Mason District Hospital - Havana
- Illinois CancerCare - Kewanee Clinic - Kewanee
- Illinois CancerCare - Macomb - Macomb
- McDonough District Hospital - Macomb
- Illinois CancerCare - Monmouth - Monmouth
- OSF Holy Family Medical Center - Monmouth
- BroMenn Regional Medical Center - Normal
- Community Cancer Center - Normal
Arizona
- Mayo Clinic Scottsdale - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2009-04 |
| Est. Completion | 2017-06-15 |
| Phase | Phase 1 |
What the finished NCT00787969 record still lists
NCT00787969 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Filgrastim is the first listed.
NCT00787969 names 20 study sites across 2 states, led by Illinois, Arizona.
Frequently Asked Questions
What is clinical trial NCT00787969 about?
NCT00787969 is a clinical study titled "Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma". This phase I/II trial studies the side effects and best dose of temsirolimus when given together with cladribine and rituximab and to see how well it works in treating patients with newly diagnosed mantle cell lymphoma. Monoclonal antibodies, such as rituximab, may interfere with the ability of canc...
What is the current status of trial NCT00787969?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2009-04. Estimated completion is 2017-06-15.
What conditions does trial NCT00787969 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00787969?
The interventions under investigation include: Filgrastim (BIOLOGICAL), Pegfilgrastim (BIOLOGICAL), rituximab (BIOLOGICAL), temsirolimus (DRUG), cladribine (DRUG).
Who is sponsoring clinical trial NCT00787969?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00787969 being conducted?
This trial has 20 study locations across Arizona, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00787969's enrollment target sits among peer trials
74 113th of 299 higher than 186 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422731 · 74 participants · Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- NCT03804853 · 74 participants · NA
Rehabilitation Following Reverse Total Shoulder Arthroplasty
- NCT04065776 · 74 participants · NA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
- NCT04771156 · 74 participants · Phase 4
Ketorolac in Palatoplasty
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia